Apellis Pharma gains as J.P.Morgan upgrades rating on eye drug sales
06/10/2023 11:46
** Drugmaker Apellis Pharmaceuticals' APLS.O shares rise
7.1% to $42.46 premarket
** Brokerage J.P.Morgan upgrades its rating on the company's
shares to "overweight" from "neutral"; raises PT to $81 from $60
** Brokerage sees strong Q3 sales for company's eye disorder
drug Syfovre being an upside for shares
** 12 of 15 brokerages rate the stock "buy" or higher, 3
"hold"; median PT $70 - LSEG data
** As of last close, stock down 23.3% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))